Alpha-1 antitrypsin inhibits SARS-CoV-2 infection

  1. Lukas Wettstein
  2. Carina Conzelmann
  3. Janis A. Müller
  4. Tatjana Weil
  5. Rüdiger Groß
  6. Maximilian Hirschenberger
  7. Alina Seidel
  8. Susanne Klute
  9. Fabian Zech
  10. Caterina Prelli Bozzo
  11. Nico Preising
  12. Giorgio Fois
  13. Robin Lochbaum
  14. Philip Knaff
  15. Volker Mailänder
  16. Ludger Ständker
  17. Dietmar Rudolf Thal
  18. Christian Schumann
  19. Steffen Stenger
  20. Alexander Kleger
  21. Günter Lochnit
  22. Konstantin Sparrer
  23. Frank Kirchhoff
  24. Manfred Frick
  25. Jan Münch
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified α1-antitrypsin (α1-AT) as specific inhibitor of SARS-CoV-2. α1-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations. Our findings show that endogenous α1-AT restricts SARS-CoV-2 and repurposes α1-AT-based drugs for COVID-19 therapy.

Related articles

Related articles are currently not available for this article.